NCT00920725 - Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

December 31, 2007

Conditions

Diabetic Ketoacidosis

Interventions

DRUG

Insulin (Aspart Insulin [Novolog], Regular Insulin)

"Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous"

Trial Locations (1)

Rush University Medical Center, Chicago